Closing the personalized medicine information gap: HER2 test documentation practice (Q37573749)

21 August 2017

Closing the personalized medicine information gap: HER2 test documentation practice (English)

1 reference

21 August 2017

personalized medicine

1 reference

Ilia L Ferrusi

1

1 reference

21 August 2017

Craig C Earle

2

1 reference

21 August 2017

Maureen Trudeau

3

1 reference

21 August 2017

Natasha B Leighl

4

1 reference

21 August 2017

Eleanor Pullenayegum

5

1 reference

21 August 2017

Hoa Khong

6

1 reference

21 August 2017

Jeffrey S Hoch

7

1 reference

21 August 2017

Deborah A Marshall

8

1 reference

21 August 2017

1 January 2013

1 reference

American Journal of Managed Care

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

1

1 reference

21 August 2017

838-844

1 reference

Genomic testing and therapies for breast cancer in clinical practice.

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

HER2 evaluation and its impact on breast cancer treatment decisions

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

The changing global patterns of female breast cancer incidence and mortality

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3919466

Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23379747

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Protocol for the examination of specimens from patients with invasive carcinoma of the breast

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23379747

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23379747

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

21 August 2017

1 reference